Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure

Jarrad M Scarlett, Darren D Bowe, Xinxia Zhu, Ayesha K Batra, Wilmon F Grant and Daniel L Marks

Department of Pediatrics, Oregon Health and Science University, Mailcode L481, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA

Correspondence should be addressed to D L Marks; Email: marksd@ohsu.edu

Abstract

The central melanocortin system plays a key role in the regulation of food intake and energy homeostasis. We investigated whether genetic or pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in mice and rats with heart failure. Permanent ligation of the left coronary artery (myocardial infarction (MI)) or sham operation was performed in wild-type (WT) or melanocortin-4 receptor (MC4R) knockout mice. Eight weeks after surgery, WT-Sham mice had significant increases in lean body mass (LBM; \(P<0.05\)) and fat mass \(P(0.05)\), whereas WT-MI did not gain significant amounts of LBM or fat mass. Resting basal metabolic rate (BMR) was significantly lower in WT-Sham mice compared to WT-MI mice \((P<0.001)\). In contrast, both MC4-Sham and MC4-MI mice gained significant amounts of LBM \((P<0.05)\) and fat mass \((P<0.05)\) over the study period. There was no significant difference in the BMR between MC4-Sham and MC4-MI mice. In the second experiment, rats received aortic bands or sham operations, and after recovery received i.c.v. injections of either artificial cerebrospinal fluid (aCSF) or the melanocortin antagonist agouti-related protein (AGRP) for 2 weeks. Banded rats receiving AGRP gained significant amount of LBM \((P<0.05)\) and fat mass \((P<0.05)\) over the treatment period, whereas banded rats receiving aCSF did not gain significant amounts of LBM or fat mass. These results demonstrated that genetic and pharmacologic blockade of melanocortin signaling attenuated the metabolic manifestations of cardiac cachexia in murine and rat models of heart failure.

Journal of Endocrinology (2010) 206, 121–130

Introduction

Chronic heart failure (CHF) is a major public health problem in western countries, with an incidence approaching 10 per 1000 population per year in those aged 65 years or older (Cowie et al. 1999, Lloyd-Jones et al. 2002). In the United States, CHF contributed to \(\sim 284\) 365 deaths in 2004, and the estimated direct and indirect health care costs to patients with CHF for 2008 were $34.8 billion (Rosamond et al. 2008). The prognosis of CHF patients is significantly worsened by the development of cachexia, a wasting condition that also manifests itself in other chronic illnesses, including cancer, chronic renal failure, AIDS, and inflammatory bowel disease (Tisdale 1997). Cardiac cachexia is a complex metabolic disorder involving features of anorexia, catabolism of protein and fat, reductions in bone mineral density, activation of acute phase response, and insulin resistance (Tisdale 1997). CHF patients that develop cardiac cachexia have increased morbidity and mortality compared to CHF patients who do not become cachectic, an effect that is independent of left ventricular function (Anker et al. 1997). Indeed, one study demonstrated that the mortality at 18 months in CHF patients that had been diagnosed with cardiac cachexia was as high as 50% compared with 17% in patients with CHF that did not develop cardiac cachexia (Anker et al. 1997).

Although the exact molecular mechanisms that initiate and maintain the cachectic state in CHF remain largely unresolved, there is increasing evidence to suggest that increased production of proinflammatory factors including cytokines, chemokines, and eicosanoids may play a crucial role in the pathogenesis of cardiac cachexia. Specifically, there has been an increased focus placed on the potential role of proinflammatory cytokines in the pathogenesis of cardiac cachexia, as elevated serum levels of tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), interleukin-1\(\beta\) (IL-1\(\beta\)), and IL-6 have been measured in CHF patients with cardiac cachexia (Levine et al. 1990, Dutka et al. 1993, Anker et al. 1999).

Administration of proinflammatory cytokines, either peripherally or centrally, induces anorexia, weight loss, and activation of the hypothalamic–pituitary–adrenal axis (Plata-Salaman et al. 1996, Plata-Salaman 2001). The metabolic and behavioral responses elicited by proinflammatory cytokines are hypothesized to occur via their interaction with circuits in the central nervous system that regulate metabolism and food intake (Campbell 1998, Reyes & Sawchenko 2002).
A candidate target for inflammatory cytokines in the brain is the central melanocortin system. The central melanocortin system plays a critical role in the regulation of feeding behavior, linear growth, and metabolic rate (Baskin et al. 1999, Cone et al. 2001). This occurs principally via the action of α-melanocyte-stimulating hormone (α-MSH), a peptide derived from the proopiomelanocortin (POMC)—expressing neurons in the hypothalamus and brainstem (Cone 2005). The feeding and metabolic effects of α-MSH are mediated by the melanocortin-4 receptor (MC4R), a G protein-coupled receptor expressed predominately in the brain (Cone 2005). Acute and chronic stimulation of MC4R produces anorexia, weight loss, and increased metabolic rate (Fan et al. 1997, Foster et al. 2003), whereas genetic deletion or antagonism of MC4R by agouti-related protein (AGRP), an endogenous melanocortin receptor inverse agonist, promotes food intake and weight gain (Ollmann et al. 1997, Joppa et al. 2005). Recent studies have shown that the secretion of α-MSH is increased and the secretion of AGRP is decreased from hypothalamic explants in response to IL-1β (Scarlett et al. 2007, 2008), demonstrating that central melanocortin signaling can be increased in response to an inflammatory cytokine.

Data from a number of studies support a critical role for the central melanocortin system in the pathogenesis of cachexia of chronic disease. Mice with impaired central melanocortin signaling due to targeted deletion of the MC4R (MC4RKO) are resistant to the development of cachexia in models of lipopolysaccharide (LPS) sepsis (Marks et al. 2001), cancer (Marks et al. 2001), and acute renal failure (Cheung et al. 2005). Pharmacologic blockade of MC4R signaling with AGRP has been shown to attenuate cachexia in a murine model of cancer cachexia (Joppa et al. 2007). Ghrelin, a gut-derived peptide agonist for the GH secretagogue receptor that also potently inhibits central melanocortin signaling by increasing Agpr mRNA expression (Kamegai et al. 2000) and hyperpolarizing POMC neurons (Cowley et al. 2003), has been shown to attenuate the development of cachexia in rat models of CHF (Nagaya et al. 2001). Collectively, these data support a direct role for the central melanocortin system in the pathogenesis of cardiac cachexia and suggest that blockade of central melanocortin signaling may represent a potential therapy for cardiac cachexia. There is an important drawback to these studies in that the duration of the inflammatory insult was either acute (e.g. LPS injection) or subacute (e.g. cancer models), and it remains unclear whether melanocortin blockade is a realistic therapeutic target for diseases with a more indolent course (e.g. congestive heart failure, COPD).

In the present paper, we show that chronic blockade of central melanocortin signaling using genetic and pharmacologic techniques is able to attenuate the metabolic manifestations of cardiac cachexia in murine and rat models of heart failure. To our knowledge, these studies are the first to reveal a key role for the central melanocortin system in the pathogenesis of cardiac cachexia, and demonstrate the effectiveness of prolonged antagonism of melanocortin signaling in attenuating cachexia in an animal model of chronic illness.

Materials and Methods

Animals

Male wild-type (WT) C57BL/6J mice (6–8 months of age; Jackson Laboratory), MC4RKO mice (6–8 months of age; raised in C57BL/6J background), and male Wistar rats (40–50 g; Charles River Laboratories, Wilmington, MA, USA) were maintained on a normal 12 h light:12 h darkness cycle with ad libitum access to food (Purina rodent diet 5001; Purina Mills) and water. Experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and approved by the Animal Care and Use Committees of Oregon Health and Science University.

Murine myocardial infarction surgeries

Prior to the surgeries, mice were divided into four groups: WT sham-operated (WT-Sham, n = 22), WT myocardial infarcted (WT-MI, n = 23), MC4RKO sham-operated (MC4-Sham, n = 19), and MC4RKO MI (MC4-MI, n = 18). Overall surgical mortality was 14% for WT-Sham group, 35% for WT-MI group, 11% for MC4-Sham group, and 39% for MC4-MI group. Permanent myocardial infarcts were produced in WT and MC4RKO mice by ligation of the anterior descending branch of the left coronary artery as previously described (Gould et al. 2002). Briefly, mice were anesthetized with i.p. pentobarbital sodium (4 mg/ml, 14 μl/g body weight (BW), Nembutal, Abbott Laboratories), placed in a supine position, and intubated. Mice were ventilated with a mixture of 100% oxygen and room air with a mechanical rodent Mini-Vent ventilator (100 cycles/min, Harvard Apparatus, Holliston, MA, USA). Ventilator stroke volume was adjusted to fully inflate but not overexpand the lungs. A lateral sternotomy was performed, exposing the anterior surface of the heart. The anterior descending branch of the left main coronary artery (LAD) was ligated at a position ~1 mm from the tip of the normally positioned left auricle with a 7–0 polypropylene monofilament suture (Prolene, Ethicon, Somerville, NJ, USA). The ligature was not removed after placement. Sham operations were created by passing the suture under the coronary artery at the position used for ligation without ever constricting the artery. After chest closure, mice were recovered in a sternal position, warmed, and provided with 100% oxygen by nose cone. Post-operative analgesia was extended with a single s.c. injection of 2.5 mg/kg buprenorphine (Buprenex, Reckitt and Colman Pharmaceuticals; Richmond, VA, USA). Mice must have survived 8 weeks after surgery to be included in the body composition and indirect calorimetry studies.

Murine body composition

Body composition was determined before infarction surgeries and the end of the experiment by dual-energy X-ray absorptiometry (DEXA, PIXImus mouse densitomete,
MEC Lunar Corp., Minster, OH, USA). The instrument was calibrated at the start of each recording session with a murine calibration standard. All animals were fasted for 12 h before DEXA analysis to minimize the effect of ingested food on the DEXA analysis. Individual organ weights (including heart, liver, lung, and spleen) were measured at necropsy at the end of the final DEXA scan.

**Murine indirect calorimetry**

Oxygen consumption (VO$_2$) was determined by indirect calorimetry (Oxymax, Columbus Instruments, Columbus, OH, USA). Mice were housed in separate chambers at 24±1 °C. Mice were first acclimatized to the chambers for 2 days prior to conducting the study. Measurements were recorded for 4–8 h during the middle of the light cycle (1100–1600 h). Samples were recorded every 3 min with the room air reference taken every 30 min and the air flow to chambers 500 ml/min. Basal oxygen consumption was determined for individual curves as the average of the lowest plateau regions corresponding to resting periods. Total oxygen consumption was the result of all samples recorded corresponding to periods of movement as well as inactivity.

**Rat aortic banding surgeries**

Male Wistar rats (n=40) were anesthetized by i.p. injection of pentobarbital sodium (60 mg/kg BW). Rats were ventilated with a mixture of 100% oxygen and room air by mechanical ventilation at a tidal volume of 320 μl and a frequency of 120 bpm (MiniVent, Harvard Apparatus). Aortic stenosis (n=22) was induced via a left thoracic incision by banding the ascending aorta with titanium clips (Weck Atraucilp, 0·6 mm internal diameter) as previously described (Helies-Toussaint et al. 2005). The Sham group consisted of sham-operated rats (n=18) prepared by a similar surgical treatment without placement of the clip. After chest closure, rats were recovered in a sternal position, warmed, and provided with 100% oxygen by nose cone. Post-operative analgesia was extended with a single s.c. injection of 2·5 mg/kg buprenorphine. Surgical mortality was 18% for banded rats and 11% for sham-operated rats. The rats were group housed until the sham-operated rats reached an average weight of 200 g, at which time both sham-operated and banded rats were separated into individual cages for food intake and BW measurement studies.

**Rat i.c.v. cannulation and injections**

Cannulation implantation was performed when the average weight of the sham-operated rats reached 300 g. Sham- and aortic-banded rats were anesthetized as described above and placed in a stereotaxic apparatus (Cartesian Research, Inc., Sandy, OR, USA). A sterile guide cannula with obturator stylet was implanted 1 mm lateral to bregma, 1·5 mm posterior to bregma, and 3·6 mm below the surface of the skull. The cannula was then fixed in place with dental cement. After surgery, the rats were divided into four groups: sham-operated, artificial cerebrospinal fluid (aCSF)-treated (Sham-aCSF, n=8); sham-operated, AGRP treated (Sham-AGRP, n=8); banded, aCSF-treated (Band-aCSF, n=9); and banded, AGRP-treated (Band-AGRP, n=9), and remained individually housed and allowed 5 days to recover before receiving their first DEXA scan and beginning the treatment period. During recovery, the rats were handled daily and administered 5 μl i.c.v. injections of commercial aCSF (Harvard Apparatus) daily. During the 2-week treatment period, animals received 5 μl injections of either aCSF or 1 nmol AGRP (Phoenix Pharmaceuticals, Burlingame, CA, USA) dissolved in 5 μl aCSF once every 48 h for a total of eight injections. One Band-AGRP, two Band-aCSF, and two Sham-aCSF rats lost their cannulas prior to the completion of the 2-week treatment period, and were excluded from the final analysis.

**Rat body composition**

Body composition was determined before and after the 2-week AGRP or aCSF treatment period by DEXA (Hologic QDR Discovery A Densitometer) at the OHSU General Clinical Research Center Body Composition core. All animals were fasted for 12 h before DEXA analysis to minimize the effect of ingested food on the DEXA analysis. Individual organ weights were measured at necropsy at the end of the final DEXA scan. Feed efficiency was calculated by dividing the total weight gained by the total amount of food consumed over the 14-day treatment period. The ratio of lean body mass (LBM) to total body water was determined using quantitative magnetic resonance (EchoMRI, Houston, TX, USA) by the Cincinnati Mouse Metabolic Phenotyping Center as previously described (Tinsley et al. 2004).

**Organ necropsy**

A macroscopic necropsy was done for each animal at the time of killing. The heart was removed, the atria and great vessels were removed, and the combined weight of the ventricles and septum was weighed. The liver and kidneys were also removed and weighed. Rat brains were removed, and hypothalamic blocks were dissected out and stored in RNAlater (Ambion, Inc., Austin, TX, USA) at −80 °C.

**RNA preparation and reverse transcription-PCR**

Total RNA was extracted from mice and rat hypothalamic blocks and rat calf muscle using Qiagen RNeasy kits (Qiagen, Inc.). DNA was removed from total RNA using RNase-free DNase (Qiagen Inc). Reverse transcription (RT) reactions were prepared using a TaqMan RT Kit (Applied Biosystems, Inc., Foster City, CA, USA).

Real-time RT-PCR was performed on an ABI 7300 Real-Time PCR System using rat-specific primer probe sets obtained from Applied Biosystems. Samples and endogenous
controls (Eukaryotic 18s rRNA) were run in duplicate to assure repeatability. Auto C\textsubscript{i} values were calculated using 7300 RQ Study Software v.1.3 and verified.

**Serum TNF-α measurement**

Blood samples were collected in disodium EDTA vacutainers with added aprotinin (500 KIU/ml of blood) and centrifuged at 1600 \( g \) for 15 min at 4 °C. Serum samples were stored at \(-80^\circ C\) until assayed for TNF-α. Serum TNF-α concentrations were determined using species-specific, commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA) following the manufacturer’s protocol. Radioactive counts were measured using an automated gamma-counter (Beckman LS6500). All samples were run in duplicate.

**Statistical analysis**

Data are expressed as mean ± s.e.m. for each group. Statistical analysis was performed using SPSS (v. 14.0; Chicago, IL, USA) and Prism (v. 5.0) software. Comparisons of data between the four groups were made with one-way ANOVA, followed by a post-hoc analysis using a Bonferroni multiple comparison test. Changes during treatment were analyzed with a two-way ANOVA for repeated measures followed by a comparison test. Changes during treatment were analyzed with one-way ANOVA, followed by a post-hoc analysis using a Bonferroni multiple comparison test. Results of data analysis were compared by a log-rank test for homogeneity. For all analyses, significance was assigned at the \( P<0.05 \) level.

**Table 1** Characterization of wild-type versus MC4RKO mice. Data are expressed as mean ± s.e.m.

<table>
<thead>
<tr>
<th>Number</th>
<th>WT-Sham</th>
<th>WT-MI</th>
<th>MC4-Sham</th>
<th>MC4-MI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Body weight (g)</strong></td>
<td>19</td>
<td>15</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>Baseline</td>
<td>30.82 ± 0.78</td>
<td>30.44 ± 0.92</td>
<td>43.02 ± 1.20*</td>
<td>42.75 ± 1.55*</td>
</tr>
<tr>
<td>After treatment</td>
<td>39.93 ± 1.37*</td>
<td>29.77 ± 1.02</td>
<td>51.68 ± 1.09*</td>
<td>52.26 ± 1.24*</td>
</tr>
<tr>
<td><strong>Food intake (g/day)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>4.54 ± 0.08</td>
<td>4.37 ± 0.11</td>
<td>6.75 ± 0.15*</td>
<td>6.78 ± 0.17*</td>
</tr>
<tr>
<td>8 weeks</td>
<td>14.81 ± 0.29</td>
<td>14.47 ± 0.52</td>
<td>15.91 ± 0.67</td>
<td>15.99 ± 0.65</td>
</tr>
<tr>
<td>Heart (g)</td>
<td>0.16 ± 0.01</td>
<td>0.32 ± 0.01*</td>
<td>0.18 ± 0.01</td>
<td>0.32 ± 0.01*</td>
</tr>
<tr>
<td>HW:BW ratio (mg/g)</td>
<td>4.13 ± 0.19</td>
<td>10.96 ± 0.57*</td>
<td>3.53 ± 0.11</td>
<td>6.20 ± 0.19*</td>
</tr>
<tr>
<td>HW:LBM ratio (mg/g)</td>
<td>6.39 ± 0.17</td>
<td>13.70 ± 0.13*</td>
<td>5.90 ± 0.21</td>
<td>10.45 ± 0.35*</td>
</tr>
<tr>
<td>Lung (g)</td>
<td>0.21 ± 0.01</td>
<td>0.29 ± 0.06*</td>
<td>0.26 ± 0.01*</td>
<td>0.32 ± 0.02*</td>
</tr>
<tr>
<td>Lung:BW ratio (mg/g)</td>
<td>5.50 ± 0.29</td>
<td>10.05 ± 0.61*</td>
<td>4.14 ± 0.18</td>
<td>6.05 ± 0.42*</td>
</tr>
<tr>
<td>Kidney (g)</td>
<td>0.24 ± 0.01</td>
<td>0.20 ± 0.01*</td>
<td>0.25 ± 0.01*</td>
<td>0.23 ± 0.01*</td>
</tr>
<tr>
<td>Kidney:BW ratio (mg/g)</td>
<td>6.10 ± 0.28</td>
<td>6.75 ± 0.23</td>
<td>4.81 ± 0.16*</td>
<td>4.49 ± 0.25*</td>
</tr>
<tr>
<td>Liver (g)</td>
<td>1.30 ± 0.06</td>
<td>1.08 ± 0.03</td>
<td>3.38 ± 0.20*</td>
<td>2.92 ± 0.19*</td>
</tr>
<tr>
<td>Lean body mass (g)</td>
<td>3.51 ± 0.14</td>
<td>3.63 ± 0.12</td>
<td>6.51 ± 0.34*</td>
<td>5.58 ± 0.31*</td>
</tr>
<tr>
<td>Baseline</td>
<td>22.58 ± 0.26</td>
<td>22.96 ± 0.39</td>
<td>27.06 ± 0.46*</td>
<td>26.95 ± 0.78*</td>
</tr>
<tr>
<td>Percentage of body weight</td>
<td>73.34 ± 1.44</td>
<td>76.28 ± 1.84</td>
<td>63.29 ± 1.16*</td>
<td>63.55 ± 2.18*</td>
</tr>
<tr>
<td>After treatment</td>
<td>25.14 ± 0.45*</td>
<td>22.83 ± 0.41*</td>
<td>30.95 ± 0.52*</td>
<td>30.70 ± 0.57*</td>
</tr>
<tr>
<td>Percentage of body weight</td>
<td>63.82 ± 1.63*</td>
<td>77.54 ± 1.98*</td>
<td>59.61 ± 0.78*</td>
<td>58.88 ± 1.17*</td>
</tr>
<tr>
<td>Fat mass (g)</td>
<td>8.27 ± 0.58</td>
<td>7.35 ± 0.56</td>
<td>16.30 ± 0.82*</td>
<td>16.37 ± 1.08*</td>
</tr>
<tr>
<td>Baseline</td>
<td>26.72 ± 1.21</td>
<td>23.82 ± 1.71</td>
<td>37.71 ± 1.11*</td>
<td>38.11 ± 1.85*</td>
</tr>
<tr>
<td>After treatment</td>
<td>14.56 ± 0.99*</td>
<td>8.11 ± 0.98*</td>
<td>20.76 ± 0.68*</td>
<td>21.81 ± 0.99*</td>
</tr>
<tr>
<td>Percentage of body weight</td>
<td>35.16 ± 1.59*</td>
<td>27.07 ± 3.22*</td>
<td>40.01 ± 0.61</td>
<td>41.55 ± 1.11*</td>
</tr>
</tbody>
</table>

WT, wild-type mice; MC4, MC4RKO mice; Sham, sham-operated mice; MI, myocardial infarction. *\( P<0.05 \) versus respective WT group; †\( P<0.05 \) versus respective Sham group; ‡\( P<0.05 \) versus respective Sham group.

**Results**

**WT mice develop cardiac cachexia following MI**

Eight weeks after surgery, the heart weights (HWs) of WT-MI mice (\( n=15 \)) were significantly increased compared to WT-Sham mice (\( n=19 \)) (WT-MI 0.32 ± 0.01 g versus WT-Sham 0.16 ± 0.01 g, \( P<0.001 \); Table 1). The HW-to-BW ratio (HW:BW), a well-established index of cardiac hypertrophy, was significantly greater for WT-MI mice compared to WT-Sham mice (WT-MI 13.7 ± 0.54 g versus WT-Sham 6.39 ± 0.17 g, \( P<0.001 \); Table 1). The wet lung weights of WT-MI mice were significantly greater than WT-Sham mice (WT-MI 0.29 ± 0.06 g versus WT-Sham 0.17 ± 0.01 g, \( P<0.001 \); Table 1). Serum concentration of TNF-α was not significantly different between WT-MI and WT-Sham mice (WT-MI 0.18 ± 0.04 pg/ml versus WT-Sham 0.11 ± 0.05 pg/ml, \( P=NS \)). WT-MI mice experienced significantly greater mortality compared to WT-Sham mice (\( P<0.001 \), Fig. 1). Of 34 WT-MI mice, 14 (41%)
MC4RKO mice resist cardiac cachexia following MI

To test the role of the MC4R in the pathogenesis of cardiac cachexia, we performed sham (MC4-Sham) and MI (MC4-MI) surgeries in MC4RKO mice. Eight weeks after surgery, the HWs of MC4-MI mice (n = 11) were significantly increased compared with MC4-Sham mice (n = 17) (MC4-MI 6.20 ± 0.19 g versus MC4-Sham 3.32 ± 0.02 g, P < 0.01; Table 1), and these values were not significantly different compared to their respective WT-Sham and WT-MI groups (P = NS; Table 1). Serum concentrations of TNF-α were not significantly different between MC4-MI and MC4-Sham mice (MC4-MI 0.19 ± 0.09 pg/ml versus MC4-Sham 0.10 ± 0.07 pg/ml, P = NS), and were not significantly different compared to WT-MI and WT-Sham mice. MC4-MI mice experienced significantly greater mortality compared with MC4-Sham mice (P < 0.001, Fig. 1). Of 19 MC4-MI mice, 11 (58%) survived to the end of the study,
compared with 17 of 20 (85%) MC4-Sham mice. A greater percentage of MC4-MI mice survived to 8 weeks after surgery compared with WT-MI mice (58 vs 41%), but this difference failed to reach statistical significance in this study. Prior to surgery, MC4-Sham and MC4-MI mice had equal baseline daily food intake (Table 1), and the daily food intake for both groups did not significantly change over the course of the study (Table 1). Both MC4-Sham mice and MC4-MI mice gained significant and comparable amounts of BW, LBM, and fat mass over the course of the study (Table 1). There was no difference in the liver weights were comparable between MC4-Sham and MC4-MI mice, and both groups were significantly higher compared to WT-Sham mice (Fig. 2). At necropsy, the kidney weights and liver weights were significantly increased by AGRP treatment in banded rats when expressed both as a percent of baseline (Band-aCSF 3.39 ± 2.50% versus Band-AGRP 17.90 ± 2.29%, P < 0.001; Fig. 4) and when expressed as absolute grams of tissue (Band-aCSF 7.12 ± 0.52 g versus Band-AGRP 12.0 ± 0.95 g, P < 0.0001). Feed efficiency was significantly decreased in sham (Sham 25.5 ± 0.95 versus Band 26.6 ± 1.05 g; P < 0.001), and had higher daily food intake (Sham 25.5 ± 0.95 versus Band 19.6 ± 0.82 g; P < 0.001). Sham-aCSF, Sham-AGRP, and Band-AGRP rats gained significant amounts of BW over the 2-week treatment period, but Band-aCSF rats failed to significantly gain weight (Table 2). Weight gain, LBM, fat mass accumulation, and kidney weights and liver weights were significantly increased by AGRP treatment in banded rats (Band-aCSF versus Band-AGRP; Table 2). The percent increase in LBM per animal over the course of the study was higher in Sham-aCSF rats compared to Band-aCSF rats (Sham-aCSF 11.6 ± 2.04% versus Band-aCSF 3.39 ± 2.50%, P < 0.05; Fig. 4). AGRP treatment significantly increased LBM per animal in banded rats when expressed both as a percent of baseline (Band-aCSF 3.39 ± 2.50% versus Band-AGRP 17.90 ± 2.29%, P < 0.001; Fig. 4) and when expressed as absolute grams of tissue (Band-aCSF 7.12 ± 0.52 g versus Band-AGRP 12.0 ± 0.95 g, P < 0.0001). Feed efficiency was significantly decreased in banded rats (Sham-aCSF versus Band-aCSF; Table 2), and significantly increased by AGRP (Band-aCSF versus Band-AGRP; Table 2). The heart and wet lung weights of banded rats were significantly increased compared with sham-operated rats.

Table 2 Characterization of sham and banded rats. Data are expressed as mean ± S.E.M.

<table>
<thead>
<tr>
<th></th>
<th>Sham-aCSF</th>
<th>Sham-AGRP</th>
<th>Band-aCSF</th>
<th>Band-AGRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>6</td>
<td>8</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>295.0 ± 5.9</td>
<td>294.1 ± 3.8</td>
<td>264.5 ± 8.7</td>
<td>268.6 ± 5.8</td>
</tr>
<tr>
<td>After treatment</td>
<td>331.3 ± 5.1²</td>
<td>367.5 ± 12.0⁴</td>
<td>272.8 ± 10.2²</td>
<td>343.3 ± 5.9¹,⁴</td>
</tr>
<tr>
<td>Food intake (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>26.12 ± 0.53</td>
<td>24.87 ± 0.86</td>
<td>18.85 ± 1.32</td>
<td>20.61 ± 0.89</td>
</tr>
<tr>
<td>During treatment</td>
<td>26.73 ± 0.99</td>
<td>33.25 ± 2.61¹,⁸</td>
<td>22.26 ± 0.69</td>
<td>34.64 ± 1.66²,⁸</td>
</tr>
<tr>
<td>Feed efficiency</td>
<td>0.12 ± 0.02</td>
<td>0.16 ± 0.03</td>
<td>0.02 ± 0.03</td>
<td>0.15 ± 0.01³</td>
</tr>
<tr>
<td>Heart weight (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>0.84 ± 0.02</td>
<td>0.87 ± 0.03</td>
<td>1.43 ± 0.02²</td>
<td>1.46 ± 0.08²</td>
</tr>
<tr>
<td>During treatment</td>
<td>0.95 ± 0.03</td>
<td>1.68 ± 0.04</td>
<td>5.39 ± 0.23</td>
<td>4.33 ± 0.15¹,⁸</td>
</tr>
<tr>
<td>Lung (g)</td>
<td>1.21 ± 0.05</td>
<td>1.20 ± 0.06</td>
<td>2.09 ± 0.34</td>
<td>2.05 ± 0.24³</td>
</tr>
<tr>
<td>Lung:BW ratio (mg/g)</td>
<td>3.64 ± 0.12</td>
<td>3.30 ± 0.24</td>
<td>7.83 ± 1.39</td>
<td>6.02 ± 0.73</td>
</tr>
<tr>
<td>Kidney (g)</td>
<td>1.32 ± 0.04</td>
<td>1.28 ± 0.04</td>
<td>1.04 ± 0.03²</td>
<td>1.23 ± 0.07³</td>
</tr>
<tr>
<td>Kidney:BW ratio (mg/g)</td>
<td>3.99 ± 0.18</td>
<td>3.56 ± 0.15</td>
<td>3.90 ± 0.19</td>
<td>3.58 ± 0.21</td>
</tr>
<tr>
<td>Liver (g)</td>
<td>12.15 ± 0.50</td>
<td>11.72 ± 0.53</td>
<td>9.07 ± 0.47¹</td>
<td>12.48 ± 0.78²</td>
</tr>
<tr>
<td>Liver (% of body weight)</td>
<td>3.69 ± 0.19</td>
<td>3.19 ± 0.13</td>
<td>3.35 ± 0.23</td>
<td>3.59 ± 0.29</td>
</tr>
<tr>
<td>Lean body mass (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>265.7 ± 3.35</td>
<td>261.0 ± 4.99</td>
<td>243.2 ± 7.12²</td>
<td>248.0 ± 5.08</td>
</tr>
<tr>
<td>Percentage of body weight</td>
<td>88.43 ± 1.41</td>
<td>87.75 ± 1.13</td>
<td>87.44 ± 2.17</td>
<td>87.79 ± 1.05</td>
</tr>
<tr>
<td>After treatment</td>
<td>298.6 ± 4.91³</td>
<td>300.4 ± 9.67²</td>
<td>251.2 ± 8.80⁴</td>
<td>298.9 ± 8.82²,³</td>
</tr>
<tr>
<td>Percentage of body weight</td>
<td>89.58 ± 0.61</td>
<td>83.70 ± 1.80¹</td>
<td>90.95 ± 0.70</td>
<td>86.11 ± 1.89</td>
</tr>
<tr>
<td>Fat mass (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>25.52 ± 1.18</td>
<td>24.30 ± 2.94</td>
<td>18.17 ± 1.68</td>
<td>17.94 ± 1.27</td>
</tr>
<tr>
<td>Percentage of BW</td>
<td>7.97 ± 0.26</td>
<td>8.79 ± 0.95</td>
<td>6.87 ± 0.59</td>
<td>6.83 ± 0.42</td>
</tr>
<tr>
<td>After treatment</td>
<td>26.91 ± 1.13</td>
<td>58.95 ± 7.72¹,⁸</td>
<td>18.46 ± 2.50</td>
<td>44.04 ± 3.61¹,³</td>
</tr>
<tr>
<td>Percentage of BW</td>
<td>8.37 ± 0.26</td>
<td>16.91 ± 1.69¹,⁸</td>
<td>7.06 ± 0.98</td>
<td>12.78 ± 1.41¹,³</td>
</tr>
</tbody>
</table>

Sham, sham-operated rats; Band, aortic-banded rats; aCSF, i.c.v. aCSF treatment; AGRP, i.c.v. AGRP treatment; BW, body weight. *P < 0.05 versus respective sham group; †P < 0.05 versus respective aCSF group; ‡P < 0.05 versus baseline.
versus Band-aCSF; ***

protection against the development of cachexia in the setting
addition to attenuating cachexia in the acute illness, loss of
compared to MC4-Sham mice. These results argue that in
LBM, fat mass, and overall normal gross organ weights as
become cachectic as shown by their normal accumulation of
atrophy. In contrast, MC4-MI mice as a group did not
reduced LBM, reduced fat mass accumulation, and organ
ligation surgeries developed physiologic abnormalities
(banded 0.21
ficantly different between banded rats and sham-operated rats
and wet lung weights between Band-aCSF and Band-AGRP
Pc2
listed in the MGI Database), and
0.14

rats (Table 2), but there was no significant difference in heart
and wet lung weights between Band-aCSF and Band-AGRP
animals. Serum concentrations of TNF-α were not signifi-
cantly different between banded rats and sham–operated rats
(banded 0.21 ± 0.08 pg/ml versus sham–operated
0.14 ± 0.09 pg/ml, P = NS). Band-aCSF rats had kidney
and liver weights that were significantly decreased compared to
Sham–aCSF rats (Table 2). AGRP treatment significantly
increased kidney and liver weights in banded rats (Band-aCSF
versus Band-AGRP; Table 2), and the final kidney and liver
weights of Band-AGRP rats were not different compared to
Sham–aCSF rats (Table 2). No significant differences in the
hypothalamic mRNA expression of Pomc, Agrp, neuropeptide
Y, Il1β, Il1r, prohormone convertase 1 (Pc1 or Psk1 as
list ed in the MGI Database), and P2 (Psk2) were
found between Sham–aCSF, Sham-AGRP, Band-aCSF, and
Band-AGRP rats. The survival rate for both banded and
sham–operated rats that received either saline or AGRP for
2 weeks was 100% over the 2-week injection period.

Discussion

In agreement with results from a previously published study
(Gould et al. 2002), WT mice that received permanent LAD
ligation surgeries developed physiologic abnormalities
consistent with a cachectic state including weight loss, reduced LBM, reduced fat mass accumulation, and organ
atrophy. In contrast, MC4-MI mice as a group did not
become cachectic as shown by their normal accumulation of
LBM, fat mass, and overall normal gross organ weights as
compared to MC4-Sham mice. These results argue that in
addition to attenuating cachexia in the acute illness, loss of
MC4R signaling is also effective in providing prolonged protection against the development of cachexia in the setting
of a chronic illness. In comparing the survival of MC4-MI
mice to WT-MI mice after surgery, we observed that a greater
percentage of MC4-MI mice survived compared to WT-MI
mice, though this difference did not achieve statistical
significance in this study. However, these results do suggest
that melanocortin blockade may confer a survival advantage
in the setting of heart failure, and that additional experiments
with larger groups of animals may be warranted to further
investigate this possibility.

Although a direct measurement of cardiac function via
Doppler ultrasound was not performed in this study, both
WT-MI and MC4-MI mice achieved HW:BW ratios that
were significantly greater than their respective sham controls.
Previous studies have demonstrated that mice with elevated
HW:BW ratios similar to those measured in our study are
consistent with the animals being in heart failure (Nahrendorf
et al. 2003, Shioura et al. 2007, 2008). In addition, the
increased wet lung weights of both WT-MI and MC4-MI
suggest that these animals had developed significant pulmonary edema, providing further support that these animals were
in a state of heart failure. One concern at the beginning of the
study is that loss of MC4R signaling could potentially alter
the sensitivity of the hearts to the effects of the MI procedure.
Ending HWs for sham–operated mice (WT-Sham versus
MC4-Sham) and MI mice (WT-MI versus MC4-MI) were
not different from each other. These results argue against the
loss of MC4R signaling providing a protective effect against
ischemic damage as a result of the MI procedure, or altering
the subsequent development of cardiohypertrophy.

To test the ability of specific blockade of central MC4R
signaling to attenuate cardiac cachexia, we utilized a
pharmacological approach by administering multiple i.c.v.
injections of AGRP to animals that had developed cardiac
cachexia. For this experiment, we decided to use a rat model
of left ventricular pressure overload hypertrophy, a well–
characterized model of cardiac cachexia (Helies-Toussaint
et al. 2005). At the beginning of the treatment period, banded
rats were hypophagic, and had reduced BWs, LBM, and fat
mass accumulation compared to sham–operated rats. AGRP
treatment in banded rats was effective in attenuating the
cachectic state as evidenced by the significant increases in
food intake, LBM, and fat mass accumulation while receiving
treatment. Feed efficiency, a measurement of weight gain per
unit of food consumed, was significantly increased by banding
and was reversed by AGRP treatment. These results support
the conclusion that the observed increases in weight, LBM, and
fat mass in Band-AGRP rats were not only due to AGRP
increasing food intake, but also due to AGRP decreasing the
increased metabolic rate that results from the banding
procedure. Although our current study was not designed to
measure the effect of AGRP treatment on morbidity in
banded rats, we observed during the treatment period that
Band-AGRP rats were more active and better groomed
compared to Band-aCSF rats. Indirect calorimetry measure-
ments may have provided some information regarding the
relative activity of the groups, but these measurements were

Figure 4 Effect of AGRP versus aCSF administration on the
accumulation of LBM in sham-operated and aortic-banded rats. 
Data are mean ± S.E.M. *P<0.05 versus Band-aCSF; **P<0.01
versus Band-aCSF; ***P<0.001 versus Band-aCSF.
not performed due to the inability of the murine chambers to be used for adult rats. Final gross HWs for sham-operated rats (Sham-aCSF versus Sham-AGRP) and banded rats (Band-aCSF versus Band-AGRP) were not different from each other respectively, demonstrating that central AGRP treatment did not promote cardiohypertrophy in sham rats, nor prevent cardiohypertrophy from occurring in banded rats. Collectively, these results reveal that blockade of central melanocortin signaling with AGRP is both sufficient and successful in attenuating cardiac cachexia in the aortic–banded rat model of pressure overload cardiac hypertrophy.

In human patients with CHF, elevated levels of the proinflammatory cytokine TNF-α have been measured in patients that have developed cardiac cachexia (Anker & Sharma 2002), and have been correlated with worsening cachexia (Dutka et al. 1993, Anker et al. 2004). In contrast to these human studies, we did not find significant increases in serum TNF-α in either our mouse or rat models of cardiac cachexia. Similar to our results, the absence of a significant rise in serum TNF-α in a murine model of MI-induced CHF has also been reported by another group (Schulze et al. 2003), raising the intriguing possibility that this may be representative of a species-specific difference between humans and rodents in the peripheral inflammatory response to CHF. In the absence of a robust peripheral TNF-α response, the question is then raised how else could inflammatory signals be relayed to the brain to increase central melanocortin signaling? One alternative hypothesis is that afferent fibers from autonomic nerves that innervate the heart relay stimulatory signals to the brain from the chronically inflamed, failing heart. Indeed, the ability of autonomic fibers that innervate the heart to stimulate the production of proinflammatory cytokines in the hypothalamus has already been demonstrated in a murine model of acute MI (Francis et al. 2004). Combined with recent data that have clearly established that central paracrine production of cytokines within the brain (by resident microglia) is both necessary and sufficient for the production of a cachectic state (Ogimoto et al. 2006, Wisse et al. 2007), it is possible in rodents that the development of cachexia in the setting of CHF is independent of a significant rise in peripheral proinflammatory cytokines. Although we found no significant differences in the hypothalamic expression of either IL1β or IL1R, there remains many additional proinflammatory cytokines capable of promoting a cachectic state including TNF-α, IL6, and leukemia inhibitory factor whose expression in the hypothalamus in the setting of CHF remains to be investigated.

In addition to being expressed in the brain, Mc4r mRNA expression has also been demonstrated in peripheral systems, including the heart and lung (Mountjoy et al. 2003). This observation raises the possibility that increased peripheral MC4R signaling may be contributing to the pathogenesis of cardiac cachexia, and that blockade of this signaling as would occur with MC4RKO mice might contribute to the prevention of cardiac cachexia. Phenotypic analysis of MC4RKO mice has failed to reveal the development of any cardiovascular abnormalities, and humans with defective MC4R genes have not been reported to suffer from increased cardiovascular problems independent of those associated with their increased risk of developing the metabolic syndrome. Our observation in this study that central injections of AGRP, a neuropeptide that is incapable of crossing the blood–brain barrier, are able to attenuate cardiac cachexia in our rat model of CHF strongly suggests that central MC4R signaling is the principle driving force for the cachectic state, and that the relative contribution of MC4R signaling from the periphery is likely minor. Although the functional role of MC4R signaling in the cardiorespiratory system remains to be elucidated, there is evidence that the MC3R plays a protective role in acute and delayed heart reperfusion injury (Mioni et al. 2003, Getting et al. 2004). Activation of MC3R led to reduced myocardial cytokine production and myeloperoxidase activity, and these effects were prevented by the mixed MC3/4R antagonist SHU9119, but not by the selective MC4R antagonist HS204 (Getting et al. 2004).

An interesting observation in our study was that the blockade of central melanocortin signaling resulted in significantly increased adiposity in rats with cardiac cachexia due to left ventricular pressure overload hypertrophy. Repeated injections of AGRP have been shown to cause hyperphagia and obesity in healthy rats and mice (Small et al. 2001). However, this is the first study that shows that these results also occur in rodents that have cardiac cachexia at baseline. Although increased adiposity is a risk factor for cardiovascular disease and the subsequent development of CHF (Kenchaiah et al. 2002), data suggest that once CHF has developed, overweight and obese patients paradoxically have better prognosis and lower mortality risks than lean patients (Curtis et al. 2005). Band-AGRP rats had significantly more fat mass than Sham-aCSF rats (Table 2), but unlike MC4RKO mice where the increased adiposity has the adverse outcome of pronounced liver steatosis, we did not observe liver steatosis in the Band-AGRP rats.

In summary, our data suggest that the central melanocortin system, a neural integrator of hormone and cytokine signaling that regulates feeding behavior, linear growth, and metabolic rate, may play a key role in the pathogenesis of cardiac cachexia.

The ability of genetic and pharmacologic blockade of melanocortin signaling to increase both LBM and fat mass in rodent models of CHF suggests that compounds that selectively antagonize central melanocortin signaling may have important pharmacotherapeutic benefits for cachectic CHF patients.

Declaration of interest

DLM is a consultant for IPSEN, Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict has been reviewed and managed by the OHSU Conflict of Interest in Research Committee and the Integrity Program Oversight Council.
Melanocortin blockade attenuates cardiac cachexia · J M SCARLETT and others

**Funding**

This work was supported by a National Institute of Diabetes and Digestive and Kidney Diseases Grant DK70333 and an American Heart Association Predoctoral Fellowship 0515502Z.

**References**


Ogimoto K, Harris MK Jr & Wisse BE 2006 MyD88 is a key mediator of anorexia, but not weight loss, induced by lipopolysaccharide and interleukin-1 beta. *Endocrinology* 147 4445–4453.


**www.endocrinology-journals.org**


Shioura KM, Geenen DL & Goldspink PH 2007 Assessment of cardiac function with the pressure–volume conductance system following myocardial infarction in mice. **American Journal of Physiology. Heart and Circulatory Physiology** **293** H2870–H2877.


Tisdale MJ 1997 Biology of cachexia. **Journal of the National Cancer Institute** **89** 1763–1773.


Received in final form 15 March 2010
Accepted 6 April 2010
Made available online as an Accepted Preprint
6 April 2010